Flow Cytometry for CD235a (Glycophorin A) on Red Blood Cells
This test measures the presence of CD235a (glycophorin A), a protein found on the surface of red blood cells (RBCs). It helps assess RBC membrane integrity and can identify conditions affecting RBCs.
["This test helps diagnose or monitor conditions related to RBC structure or disorders."]
Key facts at a glance
- LOINC
- 32750-2
- Short code
- CD235A
- Synonyms
- CD235a Cells NFr Spec
- Category
- chemistry
- Sample
- serum
- Container
- Lavender-top (EDTA) tube for peripheral blood; heparinized syringe or EDTA tube for bone marrow aspirate; sterile container for body fluid or tissue specimens
- Units
- N/A
- Fasting
- false
- Population
- adult
- Sex
- all
- Age range
- 18–65 years
- Method
- Flow cytometry immunophenotyping using fluorescently labeled antibodies against CD235a (glycophorin A)
- CPT
- 88184
- SNOMED
- 395149003
- Specimen volume
- Peripheral blood: 3-5 mL whole blood in EDTA; Bone marrow aspirate: 1-3 mL in EDTA; minimum 0.5 mL for pediatric or limited specimens
- Stability
- Specimen should be processed within 24-48 hours of collection when stored at 2-8°C. Optimal viability maintained when analyzed within 24 hours at room temperature (18-25°C). Do not freeze whole blood specimens.
- Hemolysis max
- 500
- Lipemia max
- 1000
- Icterus max
- 500
- TAT
- 24–72 hours
- Order
- routine
Why Is This Test Done?
Your healthcare provider may order this test if you have symptoms like anemia, hemolysis (destruction of RBCs), or other blood-related conditions that might involve changes in RBC surface proteins. It can also be part of a broader evaluation for inherited or acquired RBC disorders.
What Does the Test Involve?
A small blood sample is drawn from a vein, typically in your arm. The sample is then analyzed using flow cytometry to detect and measure CD235a on your RBCs. This process helps identify abnormalities in RBC surface markers.
Sample Collection and Preparation
The blood sample is processed and tested immediately or within a short timeframe to ensure accurate results. No special preparation is needed before the test.
What Are the Results Used For?
Results help determine if you have conditions like hereditary spherocytosis, elliptocytosis, or other RBC membrane disorders. They may also guide treatment decisions or monitor disease progression.
Reference range
Interpretive reporting; results expressed as percentage of CD235a-positive cells relative to total viable cells. Reference ranges vary by clinical context and specimen type. Peripheral blood typically shows CD235a+ erythroid cells in low percentages; bone marrow specimens demonstrate higher percentages reflecting normal erythropoiesis.N/A
No special patient preparation required for peripheral blood specimens. For bone marrow aspirates, standard pre-procedure consent and sedation protocols apply per institutional guidelines.
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
◆Associated findings1
Short name
CD235a RBC Flow Cytometry
Frequently asked questions
What does a CD235a RBC flow cytometry test measure?
How long does it take to get results from this test?
Can I eat or drink anything before this test?
Sources
- 1
- 2Lab Tests OnlineSource
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy